Metabolic Anomolies Associated With the 6 Month Clinical Evolution of Patients Suffering From Motor Conversion Disorder

NCT02329626 | Completed

• 2 other identifiers: LOCAL/2014/ETIC-012014-A01159-38
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 3

Brief Summary

The main objective of this study is to make a first evaluation of the relationship between metabolic abnormalities objectified by Positron emission tomography with 2-deoxy-2-\[fluorine-18\]fluoro- D-glucose integrated with computed tomography (PET CT 18 FDH) performed at rest at the onset of symptoms in patients with a first episode of motor conversion disorder and the persistence of a motor disability at 6 months measured by the modified Rankin score (mRS).

Conditions

Conversion Disorder

Outcome Measures

Primary Outcomes (2)

• Presence/absence of a modified Ranking score > 1

  6 months

• Presence/absence of a metabolic anomoly according to PET CT 18 FDG

  PET CT 18 FDG = Positron emission tomography with 2-deoxy-2-\[fluorine-18\]fluoro- D-glucose integrated with computed tomography

  Day 0 to Day 15

Secondary Outcomes (18)

• Presence/absence of a metabolic anomoly according to PET CT 18 FDG

  3 months

• Modified Rankin Score

  3 months

• Modified Rankin Score

  6 months

• EDSS score

  Day 0 to Day 15

• EDSS score

  3 months

Study Arms (1)

Study population

The study population consists of patients with paralysis, motor weakness or abnormal movements meeting DSM-IV criteria for motor conversion disorder consulting via the Emergency or Neurology department of participating centers. Intervention: PET CT 18 FDG

Device: PET CT 18 FDG

Interventions

PET CT 18 FDG DEVICE

Positron emission tomography with 2-deoxy-2-\[fluorine-18\]fluoro- D-glucose integrated with computed tomography. This intervention is required for the observational needs of the study.

Study population

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

The study population consists of patients with paralysis, motor weakness or abnormal movements meeting DSM-IV criteria for motor conversion disorder consulting via the Emergency or Neurology department of participating centers.

You may qualify if:

• The patient must have given free and informed consent and signed the consent
• The patient must be affiliated with or beneficiary of a health insurance plan
• The patient meets DSM-IV criteria for motor conversion disorder (with paralysis, motor weakness or abnormal movements) lasting for less than 1 month and euthymic (HAMD score \< or = 7, as evaluated by a psychiatrist)
• First episode (incident cases)
• The latest symptom dates to within a month
• The patient is not under neuroleptics

You may not qualify if:

• The subject is participating in another study
• The subject is under judicial protection, guardianship or curatorship
• The subject refuses to sign the consent
• It is not possible to correctly inform the patient
• The patient is pregnant, parturient or she is breastfeeding
• Specialized clinical neurological examination and brain and spinal cord MRI revealed an organic neurological cause
• The subject has a HAMD score \> 7
• The subject currently has manic/hypomanic episode, a diagnosis of substance abuse or dependency (excluding tobacco), a diagnosis of schizophrenia (any time in the past) or chronic neurological disease (active epilepsy, stroke, brain tumor)
• Suicidal or high risk for suicide (according to MINI assessment)
• Contra-indication for a PET scan
• The last symptom happened over 1 month ago
• The patient has had previous episodes (prevalent cases)

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nīmes: lead

Study Sites (3)

CHRU de Montpellier - Hôpital Gui de Chauliac

Montpellier, 34295, France

Location

CHRU de Montpellier - Hôpital Lapeyronie

Montpellier, 34295, France

Location

CHRU de Nîmes - Hôpital Universitaire Carémeau

Nîmes, 30029, France

Location

Related Publications (1)

• Conejero I, Thouvenot E, Abbar M, Mouchabac S, Courtet P, Olie E. Neuroanatomy of conversion disorder: towards a network approach. Rev Neurosci. 2018 Jun 27;29(4):355-368. doi: 10.1515/revneuro-2017-0041.

  PMID: 29252202 RESULT

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples will be taken at baseline, 3 months and 6 months.

MeSH Terms

Conditions

Conversion Disorder

Condition Hierarchy (Ancestors)

Somatoform Disorders; Mental Disorders

Study Officials

• Ismaël Conejero

  Centre Hospitalier Universitaire de Nîmes

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 29, 2014
• First Posted: December 31, 2014
• Study Start: January 29, 2016
• Primary Completion: January 15, 2018
• Study Completion: January 15, 2018
• Last Updated: November 21, 2025

Record last verified: 2018-03

Locations

FR (3)